title: Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.
abstract: OBJECTIVE
  BRCA1 mutation carriers have a high rate of both breast and ovarian cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which is used for the treatment of primary breast cancer and for the prevention of contralateral breast cancer. Our objective is to assess if tamoxifen treatment is associated with an increase in the subsequent risk of ovarian cancer among women with a BRCA1 mutation.
  
  
  METHODS
  A matched case-control study was performed. Cases were 154 women with ovarian cancer and a previous history of breast cancer. Controls were 560 women with no ovarian cancer and a history of breast cancer. All cases and controls carry a deleterious BRCA1 mutation. Cases and controls were matched for year of birth, age at diagnosis of breast cancer and country of residence. The effect of tamoxifen treatment on the risk of subsequent ovarian cancer was estimated using conditional logistic regression.
  
  
  RESULTS
  The unadjusted odds ratio for ovarian cancer, given previous tamoxifen treatment was 0.89 (95% CI 0.54-1.49, p=0.66). After adjusting for other treatments, the odds ratio was 0.78 (95% CI 0.46-1.33, p=0.36).
  
  
  CONCLUSIONS
  Tamoxifen treatment for breast cancer does not appear to increase the risk of ovarian cancer in BRCA1 mutation carriers.
authors: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
authors: Danielle
authors: D
authors: Vicus
authors: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada.
authors: Barry
authors: B
authors: Rosen
authors: Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
authors: Jan
authors: J
authors: Lubinski
authors: Department of Medicine and Genetics, University of Pennsylvania, Philadelphia, PA, USA.
authors: Susan
authors: S
authors: Domchek
authors: Clinical Genetics and Gynecology Services, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA.
authors: Noah D
authors: ND
authors: Kauff
authors: Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, NE, USA.
authors: Henry T
authors: HT
authors: Lynch
authors: Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
authors: Claudine
authors: C
authors: Isaacs
authors: Beth Israel Deaconess Hospital, Boston, MA, USA.
authors: Nadine
authors: N
authors: Tung
authors: Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
authors: Ping
authors: P
authors: Sun
authors: Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada. Electronic address: steven.narod@wchospital.ca.
authors: Steven A
authors: SA
authors: Narod
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics / Q000517:prevention & control; D016022:Case-Control Studies; D005260:Female; D019398:Genes, BRCA1; D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000139:chemically induced* / Q000235:genetics*; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D013629:Tamoxifen